OptimizeRx (NASDAQ:OPRX – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05, FiscalAI reports. The firm had revenue of $20.50 million during the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%.
OptimizeRx Stock Performance
Shares of NASDAQ OPRX traded up $0.12 during mid-day trading on Wednesday, hitting $7.04. The company had a trading volume of 324,917 shares, compared to its average volume of 422,567. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $132.11 million, a price-to-earnings ratio of 20.11 and a beta of 1.08. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $22.25. The stock’s 50-day moving average price is $5.93 and its 200-day moving average price is $6.77.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. UBS Group set a $10.00 price objective on OptimizeRx in a research report on Wednesday, May 13th. Wall Street Zen downgraded shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Lake Street Capital lowered their price target on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings cut shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Finally, Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $13.43.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Parkman Healthcare Partners LLC lifted its stake in shares of OptimizeRx by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after acquiring an additional 2,188 shares during the last quarter. BNP Paribas Financial Markets increased its position in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. AQR Capital Management LLC increased its position in shares of OptimizeRx by 18.4% during the fourth quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock valued at $178,000 after buying an additional 2,256 shares during the period. Quantbot Technologies LP bought a new position in shares of OptimizeRx in the 2nd quarter worth approximately $44,000. Finally, Barclays PLC raised its holdings in OptimizeRx by 18.7% in the fourth quarter. Barclays PLC now owns 27,441 shares of the company’s stock worth $336,000 after purchasing an additional 4,317 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.
OptimizeRx Company Profile
OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.
The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.
Featured Stories
- Five stocks we like better than OptimizeRx
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
